You just read:

Japan's Ministry of Health, Labour and Welfare (MHLW) Approves CSL Behring's IDELVION® -- The First and Only Hemophilia B Therapy with Up to 14-day Dosing Intervals

News provided by

CSL Behring

29 Sep, 2016, 09:46 ET